Barr Elizabeth Lm, Barzi Federica, Hughes Jaquelyne T, Jerums George, O'Dea Kerin, Brown Alex Dh, Ekinci Elif I, Jones Graham Rd, Lawton Paul D, Sinha Ashim, MacIsaac Richard J, Cass Alan, Maple-Brown Louise J
Menzies School of Health Research, Darwin, North Territory, Australia.
Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Nephrology (Carlton). 2018 Jul;23(7):682-689. doi: 10.1111/nep.13073.
We assessed associations between cardiometabolic risk factors and estimated glomerular filtration rate (eGFR) decline according to baseline albuminuria to identify potential treatment targets in Indigenous Australians.
The eGFR Follow-up Study is a longitudinal cohort of 520 Indigenous Australians. Linear regression was used to estimate associations between baseline cardiometabolic risk factors and annual Chronic Kidney Disease Epidemiology Collaboration eGFR change (mL/min per 1.73m /year), among those classified with baseline normoalbuminuria (urine albumin-to-creatinine ratio (uACR) <3 mg/mmol; n = 297), microalbuminuria (uACR 3-30 mg/mmol; n = 114) and macroalbuminuria (uACR ≥30 mg/mmol; n = 109).
After a median of 3 years follow-up, progressive declines of the age- and sex-adjusted mean eGFR were observed across albuminuria categories (-2.0 [-2.6 to -1.4], -2.5 [-3.7 to -1.3] and -6.3 [-7.8 to -4.9] mL/min per 1.72m /year). Although a borderline association was observed between greater baseline haemoglobin A and eGFR decline in those with macroalbuminuria (P = 0.059), relationships were not significant in those with microalbuminuria (P = 0.187) or normoalbuminuria (P = 0.23). Greater baseline blood pressure, C-reactive protein, waist-to-hip ratio and lower high-density lipoprotein cholesterol showed non-significant trends with greater eGFR decline in the presence of albuminuria.
Over a 3 year period, marked eGFR decline was observed with greater baseline albuminuria. Cardiometabolic risk factors were not strong predictors for eGFR decline in Indigenous Australians without albuminuria. Longer follow-up may elucidate the role of these predictors and other mechanisms in chronic kidney disease progression in this population.
我们根据基线蛋白尿情况评估了心血管代谢危险因素与估计肾小球滤过率(eGFR)下降之间的关联,以确定澳大利亚原住民潜在的治疗靶点。
eGFR随访研究是一项对520名澳大利亚原住民进行的纵向队列研究。在基线时尿白蛋白正常(尿白蛋白与肌酐比值(uACR)<3mg/mmol;n = 297)、微量白蛋白尿(uACR 3 - 30mg/mmol;n = 114)和大量白蛋白尿(uACR≥30mg/mmol;n = 109)的人群中,采用线性回归来估计基线心血管代谢危险因素与慢性肾脏病流行病学协作组的年eGFR变化(mL/min per 1.73m²/年)之间的关联。
经过中位数为3年的随访,在各蛋白尿类别中均观察到年龄和性别调整后的平均eGFR呈渐进性下降(分别为-2.0 [-2.6至-1.4]、-2.5 [-3.7至-1.3]和-6.3 [-7.8至-4.9] mL/min per 1.72m²/年)。虽然在大量白蛋白尿患者中观察到较高的基线血红蛋白A与eGFR下降之间存在临界关联(P = 0.059),但在微量白蛋白尿患者(P = 0.187)或尿白蛋白正常患者(P = 0.23)中,这种关系并不显著。在存在蛋白尿的情况下,较高的基线血压、C反应蛋白、腰臀比以及较低的高密度脂蛋白胆固醇与更大的eGFR下降呈非显著趋势。
在3年期间,观察到基线蛋白尿越高,eGFR下降越明显。在无蛋白尿的澳大利亚原住民中,心血管代谢危险因素并非eGFR下降的强预测因素。更长时间的随访可能会阐明这些预测因素以及其他机制在该人群慢性肾脏病进展中的作用。